IDEAYA Biosciences (IDYA) Jefferies London Healthcare Conference 2024 summary

Company overview and pipeline

• Focuses on precision medicine oncology, particularly synthetic lethality, with five clinical programs and three more candidates targeted by year-end.

• Most advanced asset, darovasertib, is in a registrational trial for first-line metastatic uveal melanoma; IDE397 is in phase II for MTAP deletion.

• Plans to provide updates on pipeline and new candidates at an R&D day in December.

Clinical trial progress and timelines

• Darovasertib trial enrollment is strong, exceeding targets, with over 150 patients enrolled; aiming for 230 for first readout.

• Median progression-free survival (PFS) readout for potential accelerated approval expected by end of next year; commercial launch projected for late 2026.

• Study is blinded with comparator arms; prior data showed median PFS above seven months, compared to historical two to three months.

• Monitoring overall survival data, with potential updates next year; targeting a six-month OS benefit for full approval.

Market opportunity and commercial strategy

• Kimmtrak’s launch in HLA-A2 positive uveal melanoma provides a benchmark, with $80M quarterly revenue and $300M+ annualized run rate; IDEAYA targets the larger A2-negative segment.

• Duration of therapy and long-term PFS could expand total addressable market; a quarter of patients remain progression-free beyond two years.

• Hired a Chief Commercial Officer with significant launch experience; plans for a focused U.S. sales force and a CRO model in Europe.